ASCO 2023

REVIEW UroToday

Viewing 1-20 of 154 articles

ASCO 2023: When Is Stereotactic Ablative Body Radiotherapy an Option?

ASCO 2023: The Role of Cytoreductive Nephrectomy and Surgical Metastatectomy

ASCO 2023: When to Play the Systemic Therapy Card

ASCO 2023: Timing of PARP Inhibition for Prostate Cancer with Defects in Homologous Recombination Repair

ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: Factors That Influence Decision-Making

ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: The Case for Triplet Therapy

ASCO 2023: Doublet and Triplet Therapy for Metastatic RCC: The Case for Doublet Therapy

ASCO 2023: A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer

ASCO 2023: Exercise to Enhance Cardiovascular Health Among Black Patients with Prostate Cancer with Androgen Deprivation Therapy: The POWER Trial

ASCO 2023: Technology-Enhanced Acceleration of Germline Evaluation for Therapy (TARGET): Results of a Randomized Controlled Trial of a Pretest Patient-Driven Webtool vs. Genetic Counseling for Prostate Cancer Germline Testing

ASCO 2023: Sequential Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Assessed by PET-Based Imaging

ASCO 2023: Prevalence of Mismatch Repair Deficiency in a Large Prospective Prostate Cancer Cohort

ASCO 2023: Helping Our Elders Survive and Thrive with Prostate Cancer: Known and Novel Intervention Strategies

ASCO 2023: Applying Risk/Benefit Considerations for Elder Patients to Current Treatment Advances in Prostate Cancer

ASCO 2023: Discussant: Combination Therapies Come of Age in Kidney Cancer

ASCO 2023: Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-up of Lenvatinib + Pembrolizumab vs Sunitinib in Patients with Advanced RCC

ASCO 2023: Digital Histopathology-Based Multimodal Artificial Intelligence Scores Predict Risk of Progression in a Randomized Phase III Trial in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

ASCO 2023: When More Is More: Treatment Intensification for Hormone-Sensitive Prostate Cancer

ASCO 2023: When Less Is More: Decreasing Exposure to Systemic Therapy for Hormone-Sensitive Prostate Cancer

ASCO 2023: Management of Prostate Cancer in Older Adults: Assessment and Decision Tools for Balancing Survival and Quality of Life

1
2
3
4
5
6
7
8